发明申请
US20080261863A1 Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
审中-公开
血管活性肽（Vip）/垂体腺苷酸环化酶活化肽（Pacap）受体2（Vpac2）激动剂和使用方法的PEG化
- 专利标题： Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
- 专利标题（中）： 血管活性肽（Vip）/垂体腺苷酸环化酶活化肽（Pacap）受体2（Vpac2）激动剂和使用方法的PEG化
-
申请号： US11632465申请日： 2005-06-10
-
公开(公告)号： US20080261863A1公开(公告)日： 2008-10-23
- 发明人: James Whelan , Clark Pan
- 申请人： James Whelan , Clark Pan
- 申请人地址： US CT West Haven
- 专利权人： Bayer Pharmaceuticals Corp
- 当前专利权人： Bayer Pharmaceuticals Corp
- 当前专利权人地址： US CT West Haven
- 国际申请： PCT/US05/20469 WO 20050610
- 主分类号： A61K38/28
- IPC分类号： A61K38/28 ; C07K14/00 ; C07H21/00 ; C12N15/63 ; C12N5/00 ; A61P3/10 ; C12P21/00 ; C07K1/107 ; A61K38/16
摘要：
This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods are useful in providing a treatment option for those individuals afflicted with a metabolic disorder such as diabetes, impaired glucose tolerance, metabolic syndrome, or prediabetic states, by inducing glucose-dependent insulin secretion in the absence of the therapeutically limiting side effect of reducing or lowering blood pressure.
信息查询
IPC分类:
